Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ADK | P55263 | 6/20 | 0.44 |
| ▸ | GAPDH | P04406 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HRAS | P01112 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10131159 | 0.93 | MEN1 (0.49) | LMNAENPP1MEN1USP2POLB | |
| SCHEMBL30536338 | 0.93 | MEN1 (0.49) | LMNAENPP1MEN1USP2POLB | |
| SCHEMBL10160533 | 0.93 | MEN1 (0.49) | LMNAENPP1MEN1USP2POLB | |
| SCHEMBL20214417 | 0.93 | MEN1 (0.49) | LMNAENPP1MEN1USP2POLB | |
| SCHEMBL14644475 | 0.91 | MEN1 (0.45) | LMNAENPP1MEN1USP2POLB | |
| SCHEMBL22367753 | 0.86 | ADK (0.50) | LMNAADKSLC29A1ABCB1 | |
| SCHEMBL20058765 | 0.85 | LMNA (0.44) | LMNAADKGAPDHSLC29A1ALDH1A1 | |
| SCHEMBL14010232 | 0.85 | GAPDH (0.44) | LMNAMEN1USP2POLBKMT2A | |
| SCHEMBL31725319 | 0.84 | LMNA (0.46) | LMNAMEN1USP2POLBKMT2A | |
| SCHEMBL10160766 | 0.84 | MEN1 (0.51) | LMNAENPP1MEN1USP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | LMNA 3423/4885ENPP1 224/4885MEN1 1845/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | LMNA 3423/4885ENPP1 224/4885MEN1 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.